Drugs / Paxalisib
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05012670 | Aug 2021 → Mar 2023 | — | Kazia Therapeutics Limited | Completed | No outcome recorded |
| Phase 1 | NCT04192981 | Dec 2019 → Dec 2026 expected | metastatic malignant neoplasm in the brain, neoplastic meningitis | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03696355 | Nov 2018 → Apr 2021 | central nervous system neoplasm | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01547546 | Apr 2012 → Jan 2015 | glioblastoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07391215 | Jan 2026 → Jan 2029 expected | glioblastoma | Institute of Cancer Research, United Kingdom | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06208657 | Jul 2024 → Dec 2030 expected | brain cancer, childhood malignant neoplasm, refractory malignant neoplasm | Australian & New Zealand Children's Haematology/Oncology Group | Recruiting | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07447076 | Jun 2026 → Dec 2035 expected | atypical teratoid rhabdoid tumor | Sabine Mueller, MD, PhD | Recruiting | No outcome recorded |
| Phase 2 | NCT05183204 | Feb 2022 → Aug 2026 | glioblastoma | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT05009992 | Oct 2021 → Dec 2027 expected | diffuse midline glioma, H3 K27M-mutant, grade III glioma | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 2 | NCT04906096 | Jun 2021 → Dec 2026 expected | non-Hodgkin lymphoma, primary central nervous system lymphoma | Lakshmi Nayak, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT03994796 | Oct 2019 → Nov 2025 overdue | NTRK fusion positive cancer, metastatic malignant neoplasm in the brain | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03765983 | Feb 2019 → Apr 2024 | breast cancer | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT03522298 | May 2018 → Mar 2023 | adult glioblastoma | Kazia Therapeutics Limited | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT03970447 | Jul 2019 → Jun 2028 expected | glioblastoma | Global Coalition for Adaptive Research | Recruiting | Missed primary |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Paxalisib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05009992 ↗ |
| Known as | G-02441729 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3813842 ↗ |
| Known as | GDC-0084 | “Patients will be dosed orally with paxalisib (GDC-0084) capsules (15-mg each) at the dose and schedule to which they are assigned.” NCT03522298 ↗ |
| Known as | RG 7666 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3813842 ↗ |
| Known as | Sim-0395 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3813842 ↗ |
| Action | Inhibit | “inhibitor of PI3K and mTOR” PMID 32269051 ↗ Apr 2020 |
| Modality | Small molecule | “small-molecule inhibitor” PMID 32269051 ↗ Apr 2020 |
| Route | Oral | “GDC-0084 was administered orally, once daily” PMID 31937616 ↗ Jan 2020 |
| Target | MTOR | “inhibitor of PI3K and mTOR” PMID 32269051 ↗ Apr 2020 |